Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.870
+0.069 (8.61%)
Apr 23, 2024, 12:43 PM EDT - Market open

Company Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.

Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.

In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.

The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors.

Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Aligos Therapeutics, Inc.
Aligos Therapeutics logo
Country United States
Founded 2018
IPO Date Oct 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 66
CEO Dr. Lawrence M. Blatt MBA, Ph.D.

Contact Details

Address:
One Corporate Dr., 2nd Floor
South San Francisco, California 94080
United States
Phone (800) 466-6059
Website aligos.com

Stock Details

Ticker Symbol ALGS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001799448
CUSIP Number 01626L105
ISIN Number US01626L1052
SIC Code 2836

Key Executives

Name Position
Dr. Lawrence M. Blatt MBA, Ph.D. Chief Executive Officer, President and Chairman of the Board
Dr. Julian A. Symons DPHIL Executive Vice President and Chief Scientific Officer
Lesley Ann Calhoun CPA Executive Vice President and Chief Financial Officer
Kristina Engeseth Vice President and Head of People and Culture
Dr. Matthew W. McClure M.D. Executive Vice President and Chief Medical Officer
Dr. Sushmita M. Chanda DABT, Ph.D. Executive Vice President and Chief Development Officer
Dr. David B. Smith Ph.D. Executive Vice President and Head of Chemical Operations
Dr. Tse-I Lin Ph.D. Vice President of Early Compound Development and Belgian Site Head

Latest SEC Filings

Date Type Title
Apr 16, 2024 PRE 14A Other preliminary proxy statements
Mar 12, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 12, 2024 10-K Annual Report
Mar 12, 2024 8-K Current Report
Feb 28, 2024 8-K Current Report
Feb 28, 2024 SC TO-I/A Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals